News

ABL News

Below, you’ll find a constantly-updated list of all our latest press releases.

ABL Awarded NIAID Contract to Develop Biotherapeutics to Address Infectious Disease

  • September 21, 2016

ABL announced it is one of four prime contractors awarded a ten-year, indefinite delivery/indefinite quantity (ID/IQ) contract #HHSN272201600004I “Preclinical Services for Biopharmaceutical Product Development” by the Division of Microbiology and Infectious Diseases (DMID) within the National Institute of Allergy and Infectious Disease (NIAID)

Read More

ABL Awarded Subcontract for the Production of an Inactivated Zika Virus Vaccine

  • August 4, 2016

ABL, Inc. announced it has been awarded a subcontract by Emergent BioSolutions Inc. for the rapid transfer and GMP production of an inactivated Zika virus vaccine. The Zika vaccine program is funded by the Biomedical Advanced Research and Development Authority and represents a critical response to the developing global risk of Zika infections.

Read More

The Division of AIDS Awards ABL a Seven-Year Contract to Provide HIV Microbicide Research and Product Development Support

  • July 26, 2016

ABL, Inc. is pleased to announce the award of contract #HHSN272201600008I for the “Comprehensive Resources for HIV Microbicides and Biomedical Prevention” (CRMP) by the Division of AIDS (DAIDS) in the National Institute of Allergy and Infectious Disease (NIAID).

Read More

ABL, Inc. Announces Agreements with REGENXBIO for Process Development, Scale-Up and Clinical Manufacturing of RGX-501

  • May 24, 2016

May 24, 2016 (Rockville, MD) – ABL, Inc. (ABL), a global contract research and manufacturing organization to the biopharmaceutical industry, today announced agreements with REGENXBIO, Inc., a leading biotechnology company focused on the development, commercialization and licensing of recombinant adeno-associated virus (AAV) gene therapy based on its proprietary NAV® Technology Platform, to manufacture its lead product, RGX-501, for human clinical trials.

Read More

SillaJen Announces Commercial Manufacturing Agreement with ABL Europe For Lead Oncolytic Virus, Pexa-Vec

  • May 16, 2016

May 16, 2016 (San Francisco, Calif., USA and Strasbourg, France) --ABL to Provide Product for Ongoing Phase 3 Trial and Future Commercial Demand--

Read More

ABL Awarded 3-Year Program Extension as the Biologics Production Facility for NHLBI’s SMARTT Program

  • March 11, 2016

Rockville, MD—March 11, 2016 –- ABL is pleased to announce the National Heart, Lung and Blood Institute has awarded a three year extension for the Science Moving towards Research Translation and Therapy (SMARTT) program.

Read More

ABL Part of Team Awarded $900 Million IDIQ Contract by U.S. Army for Medical Product Research and Development

  • March 3, 2016

ABL, Inc. is pleased to announce it is a member of the Engility Corporation (formerly TASC, Inc.) team recently awarded a prime position supporting the Medical Product Research and Development (MPRD) contract for the U.S. Army Medical Research and Materiel Command.

Read More

ABL, Inc. Launches Virus Manufacturing Operations in Europe

  • February 18, 2016

Rockville, MD – February 18, 2016 – ABL, Inc. (ABL), a contract research and manufacturing organization to the biopharmaceutical industry, is pleased to announce the opening of its GMP virus manufacturing facility in Strasbourg, France.

Read More

Transgene and ABL Announce the Acquisition by ABL Europe of Transgene’s Production Asset

  • February 3, 2016

Strasbourg, France, and Rockville, MD – February 3, 2016 – Transgene SA (Euronext: TNG) a company specializing in immunotherapies, and ABL, Inc., a contract research and manufacturing organization, today announced the purchase by ABL Europe, a wholly owned subsidiary of ABL, of Transgene’s production asset situated in Illkirch, near Strasbourg. Transgene, ABL, Inc. and ABL Europe are all three members of the Institut Mérieux.

Read More

ABL, Inc. Offers Quanterix Diagnostic Platform for Ultrasensitive Biomarker Detection Through Platine Pharma Services Subsidiary

  • January 14, 2016

Rockville, MD – January 14, 2016 – Platine Pharma Services SAS (PPS), a majority owned subsidiary of ABL, Inc., is a preferred partner with Quanterix Corporation, providing new ultrasensitive assays using the single molecule measurement digital platform, Simoa.

Read More

Andrew R. Macintyre, Ph.D. Joins ABL, Inc. as Director of Immunobiology

  • September 28, 2015

ABL, Inc. (ABL), a biomedical contract research and manufacturing organization serving the biotechnology and pharmaceutical industries, today announced the hiring of Dr. Andrew Macintyre as Director of Immunobiology. In this role, Dr. Macintyre will lead ABL’s newly expanded clinical operations team, supporting our clients with assay development through to sample testing.

Read More

ABL Named Small Business Champion by Montgomery County

  • July 10, 2015

Rockville, MD – July 10, 2015 – Thank you to Montgomery County Department of Economic Development for recognizing ABL as a Small Business Champion for the work we do to support our local small business community.

Read More

ABL Successfully Completes Drug Product Manufacture of Ebola Vaccine for Clinical Trial

  • June 30, 2015

Rockville, MD – June 30, 2015 – ABL, Inc. (ABL), a contract research and manufacturing organization to the biopharmaceutical industry, is pleased to announce the successful aseptic formulation and fill of an Ebola vaccine candidate for Emergent BioSolutions Inc. (EMERGENT).

Read More

ABL Awarded National Cancer Institute Contract to Continue Groundbreaking Retroviral Research

  • March 24, 2015

Rockville, MD – March 24, 2015 – ABL, Inc., a biomedical contract research and manufacturing organization to the biotechnology and pharmaceutical industries, is pleased to announce it was awarded contract # HHSN261201500001C for the “Support for Research on Retroviral Pathogenesis, Treatment and Prevention” by the National Cancer Institute (NCI).

Read More

ABL Recognized for Supporting Fill-Finish of Novavax’s Zaire Ebolavirus Glycoprotein Nanoparticle Vaccine

  • February 13, 2015

Rockville, MD – February 13, 2015 – The release of Novavax's Zaire ebolavirus (EBOV) vaccine within three months from project initiation is described in BioProcessing Journal's Spring 2015 article "Rapid Manufacture and Release of a GMP Batch of Zaire Ebolavirus Glycoprotein Vaccine Made Using Recombinant Baculovirus-Sf9 Insect Cell Culture Technology" (BioProcessing Journal, Hahn, Timothy, et al.).

Read More

ABL Selected to Support Glioblastoma Multiforme Trial with Clinical Testing Services

  • January 20, 2015

Rockville, MD – January 20, 2015 – ABL, Inc., a contract research and manufacturing organization to the biotechnology and pharmaceutical industry, is pleased to announce that its GCLP clinical laboratory team was recently selected to provide sample processing and screening services in support of a Ph II glioblastoma multiforme (GBM) immunotherapy trial for a confidential client.

Read More

Expression Therapeutics Selects ABL for Development of Hemophilia A Factor VIII Therapy

  • August 18, 2014

Tucker, GA and Rockville, MD (August 18, 2014) – Expression Therapeutics LLC, a biotechnology company developing high expression factor VIII technologies, together with ABL, Inc., a biomedical contract research and manufacturing organization to the biopharmaceutical industry, announced today an agreement whereby ABL will perform cell line development studies to improve manufacturability and reduce the costs associated with large-scale production of recombinant factor VIII replacement therapy.

Read More

ABL, Inc. Acquires Majority Interest in Platine Pharma Services

  • July 21, 2014

Rockville, MD, USA. ABL, Inc. (ABL), a biomedical contract research and manufacturing organization to the biopharmaceutical industry, is pleased to announce the acquisition of a majority interest in Platine Pharma Services (Platine), a specialist in immunomonitoring and immunogenicity services. With laboratories located in Lyon, France, Platine helps clients in the biopharmaceutical, food, cosmetic and diagnostic industries evaluate the immunogenicity, activity and efficacy of products during R&D, preclinical and human clinical studies.

Read More

ABL’s Dr. Gerald Kovacs Moderates Panel for Biodefense Conference

  • June 5, 2014

On June 5, ABL Scientific Director Dr. Gerald Kovacs moderated a panel on Development and Approval of Medical Countermeasures at the 12th Annual Emerging Infectious Diseases + Biodefense Vaccines, Therapeutics & Diagnostics Conference in Washington, DC.

Read More

ABL supports Profectus BioSciences with preclinical efficacy studies for its subunit vaccine for HIV, IHV001

  • March 4, 2014

Rockville, MD- ABL, Inc., a biomedical contract research and manufacturing organization to the biotechnology and pharmaceutical industry, has been selected by Profectus BioSciences, Inc. (Profectus) to evaluate different delivery regimens of one of its HIV vaccine candidates.

Read More

Dr. Thomas VanCott Invited to Speak at 11th Annual Biologics Forum in Tokyo

  • January 24, 2014

ABL’s President and CEO, Dr. Thomas VanCott, will attend the 11th Annual Biologics Forum in Tokyo, Japan on January 24, 2014. Dr. VanCott has been invited to speak at the conference on advances made in HIV vaccine research through projects performed at ABL.

Read More

Statement from ABL President and CEO Dr. Thomas VanCott on Strategic Agreement with Bioqual

  • December 24, 2013

Dr. Thomas VanCott, President and CEO of ABL, Inc. comments on the strategic agreement with BioQual, Inc. and ABL’s vision for growth.

Read More

ABL Completes Manufacture of Rhabdovirus-Based Oncolytic Therapeutic Vaccine for Phase I Clinical Trial

  • November 6, 2013

ABL, Inc. (ABL) has successfully delivered the final dosage form of a Rhabdovirus-based oncolytic therapeutic vaccine to the Ottawa Hospital Research Institute (OHRI). OHRI contracted ABL to execute fill finish operations for its Rhabdovirus therapeutic vaccine including clinical labeling under current Good Manufacturing Practices (cGMPs) for use in human clinical trials.

Read More

ABL, Inc. and CALIXAR Announce Strategic Marketing Agreement

  • October 30, 2013

Rockville, MD, USA and Lyon, France (October 30, 2013) – ABL, Inc. (ABL) today announced a co-marketing agreement with CALIXAR SAS (CALIXAR). Under the terms of the agreement, ABL will extend the capabilities of its vaccine and biologics therapeutic development services by offering CALIXAR’s innovative process for native extraction and purification of membrane proteins and antigens that avoid the necessity of re-folding and mutagenesis, while maintaining functionality, structural integrity and increasing product yield.

Read More

Gerald Kovacs, Ph.D. Joins ABL, Inc. as Scientific Director

  • October 16, 2013

Rockville, MD (October 16, 2013) – ABL, Inc. (ABL), a biomedical contract research and manufacturing organization to the biotechnology and pharmaceutical industries, today announced the hiring of Dr. Gerald Kovacs as Scientific Director. In this role, Dr. Kovacs will lead ABL’s scientific operations supporting U.S. government and commercial preclinical programs and oversee the continued expansion of its clinical testing capabilities.

Read More

ABL Selected by PATH to Manufacture Novel Shigella Vaccine Candidate

  • October 1, 2013

Rockville, MD (October 1, 2013) - Advanced BioScience Laboratories, Inc. (ABL), a biomedical contract research and manufacturing organization to the biotechnology and pharmaceutical industries, announced today that it has been selected by PATH, an international nonprofit global health organization, to support the development and production of a novel Shigella vaccine candidate.

Read More

Dr. Anthony Cristillo is Speaking at the NHP B Cell Working Group Meeting at NIH

  • September 25, 2013

Dr. Cristillo will join the NHP B Cell Working Group, under the National Institute of Allergy and Infectious Diseases and Office of AIDS Research, to discuss technologies, ongoing studies, and needs of the field. He is part of the NHP B cell panel discussion on phenotyping B cells.

Read More

Dr. Maria Grazia Ferrari Spoke at the NMRC on Her Mucosal Immunology Research

  • June 19, 2013

On June 19th, Dr. Ferrari was an invited speaker for the ETEC Vaccine Program at the Naval Medical Research Center in Silver Spring, MD. Enterotoxigenic Escherichia coli (ETEC) is a common cause of bacterial diarrhea, which is a common ailment affecting deployed U.S. troops overseas and for which there is no vaccine.

Read More

ABL To Attend Biodefense Vaccines and Therapeutics Summit

  • June 12, 2013

ABL will be attending and exhibiting at the 11th Annual Emerging Diseases and Biodefense Vaccines, Therapeutics, and Diagnostics Summit in Washington, DC from June 17 to June 19.

Read More

ABL Awarded Simian Vaccine Evaluation Unit (SVEU) Contract with NIAID Worth Up To $80M

  • June 4, 2013

Advanced BioScience Laboratory, Inc. (ABL), a biomedical contract research and manufacturing organization to the biotechnology and pharmaceutical industries, announced today that it has been selected as one of three Simian Vaccine Evaluation Units (SVEUs) as part of a seven-year contract worth up to $80 million from the National Institute of Allergy and Infectious Diseases (NIAID), a division of the National Institutes of Health (NIH).

Read More

ABL Wins 7-Year NIAID Simian Vaccine Evaluation Unit Contract

  • May 1, 2013

ABL won the 7-year contract to be one of three Simian Vaccine Evaluation Units (SVEU) for the National Institute of Health and Infectious Diseases (NIAID).

Read More

ABL President and CEO Dr. Thomas VanCott Named Finalist for Tech Council of Maryland (TCM) 2013 Executive of the Year

  • April 11, 2013

TCM’s annual Executive of the Year award recognizes innovative leadership in the Maryland Life Sciences and Technology communities. Dr. VanCott is a finalist for this year’s award, which will be announced at the TCM Annual Dinner and Tech Awards Celebration on May 16, 2013.

Read More

ABL President and CEO Dr. Thomas VanCott is a Finalist for Executive of the Year

  • March 29, 2013

ABL President and CEO Dr. Thomas VanCott is one of six finalists in the running for the Executive of the Year award from the Tech Council of Maryland (TCM) . The awards will be announced at the TCM Annual Dinner and Tech Awards Celebration on May 16, 2013.

Read More

ABL Recognized for Biologics Manufacturing in Support of NHLBI-Sponsored IND

  • February 19, 2013

In the latest issue of the National Heart Lung and Blood Institute’s (NHLBI) SMARTTnews, Dr. Steven Idell of the University of Texas Health Science Center expressed his appreciation of ABL’s biologics manufacturing team for creation of a master cell bank in support of his IND for a novel fibrinolysin, single chain urokinase plasminogen activator (scuPA).

Read More

ABL 2012 Publications and Presentations

  • January 8, 2013

In 2012, ABL staff had 12 presentations and publications based on research projects performed at ABL.

Read More

ABL Announces Additions to Manufacturing and Quality Control Teams

  • November 6, 2012

Rockville, MD, November 6, 2012 - Advanced BioScience Laboratories, Inc. (ABL) announces strategic hires in Upstream Process Development and Quality Control to further enhance its support of clients’ product development needs.

Read More

ABL Awarded NIH Contract to Fund up to $102M in Biologics Manufacturing and Characterization Services

  • August 1, 2012

Rockville, MD (August 1, 2012) - Advanced BioScience Laboratories, Inc. (ABL, Inc.) announced today the award of a contract to provide the NIH National Institute of Allergy and Infectious Diseases (NIAID) with preclinical development and cGMP manufacturing support for multiple vaccine and biologic products identified by NIAID Program staff.

Read More

ABL Awarded DMID Biologics Manufacturing Contract Worth Up to $102M

  • July 25, 2012

ABL was awarded a 10 year contract with the Division of Microbiology and Infectious Diseases (DMID) to provide "Manufacture and Characterization Services for Vaccines and Other Biologics for Infectious Diseases."

Read More

ABL to Provide Cell Line Development, Process Development, and cGMP Manufacturing Services of scuPA for The University of Texas Health Science Center at Tyler

  • June 12, 2012

Rockville, MD (June 12, 2012) – Advanced BioScience Laboratories, Inc. (ABL) will perform process development and cGMP manufacturing of recombinant scuPA, an enzyme therapy candidate for patients with pleural loculation or scarring surrounding the lung. scuPA reverses a defect in clot clearance that characterizes pleural loculation. The program is led by Dr. Steven Idell of The University of Texas Health Science Center at Tyler in collaboration with Dr. Andrew P. Mazar and the Center for Developmental Therapeutics at Northwestern University in Evanston, IL.

Read More

ABL Supporting Manufacture of AlphaCores rhLCAT Protein through NHLBIs SMARTT Program

  • February 14, 2012

Ann Arbor, MI and Rockville, MD [February 14, 2012] - AlphaCore Pharma, a biopharmaceutical company, and Advanced Bioscience Laboratories (ABL), a biomedical contract research and manufacturing company, today announce funding from the National Institutes of Health, National Heart, Lung and Blood Institute (NHLBI) “Science Moving towards Research Translation and Therapy” (SMARTT) program, to manufacture recombinant human lecithin-cholesterol acyltransferase (rhLCAT) for the treatment of familial LCAT deficiency.

Read More

Inviragen Enlists ABL for Manufacture of Master Virus Seed Stock for Plague Vaccine Development

  • February 8, 2012

FORT COLLINS, CO and ROCKVILLE, MD – February 8, 2012 – Inviragen, Inc. and Advanced BioScience Laboratories Inc. (ABL), a biomedical contract research and manufacturing organization, today announced the signing of a contract manufacturing agreement between the two companies.

Read More

Trophogen Selects ABL as Contract Manufacturer for Recombinant, Human Follicle-Stimulating Hormone (rhFSH) Analog

  • January 10, 2012

Rockville, MD (January 10, 2012) – Trophogen Inc., a biotechnology company developing hormone and related growth factor analogs for human infertility, animal superovulation, and human cancers together with Advanced BioScience Laboratories Inc. (ABL), a biomedical contract research and manufacturing organization, today announced the signing of a contract manufacturing agreement between the two companies.

Read More

ABL Announces Hiring of Bioprocessing Specialist to GMP Manufacturing Team

  • December 13, 2011

Rockville, MD (December 13, 2011) - Advanced BioScience Laboratories, Inc. (ABL), a leading biomedical contract research and manufacturing organization, today announced the hiring of Dr. Claire Zhang to lead its downstream bioprocessing group. With over 15 years of industry experience, Dr. Zhang will direct development and optimization programs for ABL’s commercial and government GMP manufacturing clients.

Read More

ABL Launches New Website

  • November 14, 2011

Rockville, MD (November 14, 2011) - Advanced BioScience Laboratories, Inc. (ABL), a leading biomedical contract research and manufacturing organization, is pleased to announce the launch of a newly redesigned website at www.ablinc.com.

Read More

ABL Awarded “NIAID Preclinical Development Support” Contract with Maximum Funding of $102M Over Seven Years

  • September 14, 2011

ROCKVILLE, MD (September 14, 2011) – The National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), has awarded ABL with a contract to provide preclinical development support for promising candidates when such candidates emerge from the investigator-initiated research studies.

Read More

ABL Completes Validation of New cGMP Manufacturing Facility

  • August 28, 2011

ROCKVILLE, MD (August 28, 2011) -- Advanced BioScience Laboratories, Inc. (ABL) announced today that its new cGMP biologics manufacturing facility located in Rockville, MD has completed validation and commenced cGMP operations in support of client projects.

Read More

ABL Selected to Collaborate on a 5-Year U19 Grant in Support of New Research toward an HIV Cure

  • June 20, 2011

Rockville, MD (July 20, 2011) - Advanced BioScience Laboratories (ABL) will provide nonhuman primate support and laboratory services for the Delaney AIDS Research Enterprise (DARE), Toward an HIV-1 Cure Project U19 grant entitled “Myeloid-T cell Interactions that Sustain HIV and SIV Reservoirs during Effective Antiretroviral Therapy."

Read More

Contract Pharma: ABL Opens Newly Expanded HQ

  • June 6, 2011

Advanced BioScience Laboratories, Inc. (ABL) has opened its new research and manufacturing facility following the expansion of its vaccine and biotherapeutic product development capabilities at its new headquarters in Rockville, MD.

Read More

Washington Post – Biotech Consultants Find Fertile Ground in the DC Area

  • June 5, 2011

Rockville-based Advanced Bioscience Laboratories unveiled a 72,000-square-foot facility where its researchers plan to help other firms develop new drugs.

Read More

BioWatch: ABL Turns 50 with New Digs, Open House

  • June 3, 2011

Advanced Bioscience Laboratories, a contract research organization, marked its 50th anniversary with a new facility in Rockville.

Read More

ABL Inc. Awarded the NIH Contract for NHP Core Quantitative Viral RNA Laboratory for AIDS Vaccine Research and Development

  • March 30, 2011

Rockville, MD (March 30, 2011) - Advanced BioScience Laboratories, Inc. (ABL, Inc) was awarded the National Institutes of Health (NIH) contract for Nonhuman Primate (NHP) Core Quantitative Viral RNA Laboratory for AIDS Vaccine Research and Development in the amount of $6,892,113.

Read More

Advanced BioScience Laboratories Selected as the NHLBI Biologics Manufacturing Facility for New SMARTT Program

  • January 6, 2011

Kensington, MD (January 6, 2011) - Advanced BioScience Laboratories (ABL) has been awarded a contract with the National Heart, Lung, and Blood Institute (NHLBI) of the National Institutes of Health (NIH) to manufacture biologics for treatment and prevention of heart, lung, and blood diseases.

Read More